Sign in
AVBP Stock Price, Chart, Stats & News
ArriVent BioPharma, Inc. Common Stock
Save
1.58B
Market cap
–
Current P/E
–
Forward P/E
AVBP chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -49.92% |
ROE | -62.48% |
D/E | 0.00x |
Interest coverage ratio | – |
AVBP valuation
P/E | – |
P/S | – |
P/B | 2.68x |
P/CF | -5.13x |
P/FCF | -5.90x |
P/OCF | -5.13x |
PEG | 0.91x |
EV multiple | -5.77x |
About
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering, advancing, and bringing to market treatments addressing critical gaps in cancer patient care. The company specifically focuses on developing and commercializing targeted oncology therapies for conditions like non-small-cell lung cancer (NSCLC) and various solid tumor indications. Among its pipeline candidates are Furmonertinib, an epidermal growth factor receptor (EGFR) mutant-selective tyrosine kinase inhibitor currently undergoing a Phase 3 clinical trial for NSCLC treatment, and ARR-002.
Similar securities
Based on sector and market capitalization
Report issue